Cytrellis Biosystems, founded in Massachusetts, is a clinical-stage medical technology company focused on pioneering non-surgical solutions for skin aesthetics. The company's core mission is to develop and commercialize innovative aesthetic devices that enhance skin appearance without invasive procedures. Their flagship product, the ellacor® system, employs FDA-cleared Micro-Coring® Technology to remove unwanted skin at the microscale, offering a novel approach to addressing sagging skin.

Notable figures affiliated with Cytrellis include key investors and medical experts who support its groundbreaking research and development. The company has achieved significant milestones, including FDA clearance for its ellacor® system, which underscores its commitment to safety and efficacy. Cytrellis' impact on the aesthetic industry is marked by its potential to revolutionize skin treatment, providing non-surgical alternatives that cater to a growing market demand for minimally invasive cosmetic procedures.